Side Effects of prasterone vaginal: A Synthesis of Findings from 9 Studies

  1. Home
  2. Side Effects of prasterone vaginal
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of prasterone vaginal: A Synthesis of Findings from 9 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of prasterone vaginal: A Synthesis of Findings from 9 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Several randomized clinical trials have shown that intravaginal prasterone is effective in treating vulvovaginal atrophy in postmenopausal women. 3 Intravaginal prasterone is also effective in improving dyspareunia associated with vulvovaginal atrophy. 3 Furthermore, intravaginal prasterone may be effective in treating overactive bladder in postmenopausal women. 2 Intravaginal prasterone can improve vulvovaginal atrophy symptoms and enhance quality of life. 2

Reasons for Side Effects

Prasterone is a derivative of dehydroepiandrosterone (DHEA), a male hormone. DHEA can be converted to estrogen, a female hormone. Therefore, the use of intravaginal prasterone may result in estrogen-like effects. While intravaginal prasterone is applied locally and is thought to have minimal systemic effects, some women may experience side effects due to estrogen-like effects.

Common Side Effects

Weight Gain

Weight gain has been reported as a side effect of intravaginal prasterone. 9 Weight gain may be due to estrogen-like effects. 9

Breast Tenderness

Breast tenderness has been reported as a side effect of intravaginal prasterone. 9 Breast tenderness may be due to estrogen-like effects. 9

Bloating

Bloating has been reported as a side effect of intravaginal prasterone. 9 Bloating may be due to estrogen-like effects. 9

Side Effects Management

Weight Gain

If you are concerned about weight gain, consult your doctor. They can guide you on appropriate measures like dietary changes and exercise. Adjusting the dosage of intravaginal prasterone may also be considered.

Breast Tenderness

If you experience breast tenderness, consult your doctor. They can provide guidance on managing breast tenderness. Adjusting the dosage of intravaginal prasterone may also be considered.

Bloating

If you experience bloating, consult your doctor. They can provide guidance on managing bloating. Adjusting the dosage of intravaginal prasterone may also be considered.

Comparison Across Studies

Similarities Across Studies

Multiple studies have shown that intravaginal prasterone is effective in treating vulvovaginal atrophy in postmenopausal women. 3 Furthermore, intravaginal prasterone has been shown to be effective in improving dyspareunia associated with vulvovaginal atrophy. 3

Differences Across Studies

While intravaginal prasterone has shown potential in treating overactive bladder in postmenopausal women, 2 some studies haven't reached definitive conclusions about its efficacy in this area.

Considerations for Real-Life Application

Although intravaginal prasterone has been demonstrated to be effective in treating vulvovaginal atrophy in postmenopausal women, 3 it is not effective for all women. Additionally, as intravaginal prasterone exhibits estrogen-like effects, it could potentially increase the risk of estrogen-dependent cancers. Before considering the use of intravaginal prasterone, it is crucial to consult with your doctor and thoroughly understand the risks and benefits involved to make an informed decision.

Limitations of Current Research

Research on intravaginal prasterone is still limited. Further research is needed, especially regarding the long-term safety and efficacy of intravaginal prasterone.

Future Directions for Research

Large-scale clinical trials are needed to assess the long-term safety and efficacy of intravaginal prasterone. Comparative trials between intravaginal prasterone and other treatment options are also needed.

Conclusion

Intravaginal prasterone has the potential to be effective in treating vulvovaginal atrophy in postmenopausal women. 3 However, since intravaginal prasterone exhibits estrogen-like effects, it could potentially increase the risk of estrogen-dependent cancers. Before considering the use of intravaginal prasterone, it is crucial to consult with your doctor and thoroughly understand the risks and benefits involved to make an informed decision.

Literature analysis of 9 papers
Positive Content
7
Neutral Content
2
Negative Content
0
Article Type
3
1
1
3
9
1.

Hepatotoxicity and cutaneous reactions after antithyroid drug administration.

Author: OtsukaFumiko, NohJaeduk Y, ChinoToshiko, ShimizuTaeko, MukasaKoji, ItoKunihiko, ItoKoichi, TaniyamaMatsuo

Antithyroid drug side effects

This study investigated side effects associated with the first and second antithyroid drugs (ATDs) used in patients. The study highlights the high frequency of side effects associated with thiamazole (MMI) and propylthiouracil (PTU).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.

Author: LabrieFernand, ArcherDavid F, MartelCéline, VaillancourtMario, MontesinoMarlene

Improved sexual function
Prasterone for VVA

Intravaginal prasterone demonstrated highly positive effects on all the symptoms and signs of vulvovaginal atrophy with no significant drug-related side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).

Author: BartonDebra L, SloanJeff A, ShusterLynne T, GillPaula, GriffinPatricia, FlynnKathleen, TerstriepShelby A, RanaFauzia N, DockterTravis, AthertonPamela J, TsaiMichaela, SturtzKeren, LafkyJacqueline M, RieplMike, ThielenJacqueline, LoprinziCharles L

Improved sexual health
Improved vaginal symptoms

Vaginal dehydroepiandrosterone (DHEA) can improve vaginal symptoms and sexual health in postmenopausal women with estrogen deficiencies. A randomized controlled trial of 464 women found that both 3.25 mg and 6.5 mg DHEA significantly improved vaginal dryness or dyspareunia compared to a plain moisturizer. The 6.5 mg DHEA group also showed significantly better sexual health scores.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Dehydroepiandrosterone for women in the peri- or postmenopausal phase.

Author: ScheffersCarola S, ArmstrongSarah, CantineauAstrid E P, FarquharCindy, JordanVanessa

Enhanced sexual function
Improved wellbeing
Menopausal symptom relief
Safety concerns
Uncertainty about effectiveness

DHEA is a potential treatment for menopausal symptoms, including hot flushes, night sweats, and vaginal dryness, but its efficacy and safety remain controversial. This review will assess the evidence for DHEA in treating menopausal symptoms by evaluating randomized controlled trials and determine its potential benefits and risks.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

7.

Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.

Author: LabrieFernand, Luu-TheVan, LabrieClaude, BélangerAlain, SimardJacques, LinSheng-Xiang, PelletierGeorges

Improved well-being and libido
Increased bone mineral density
Inhibition of breast cancer development and growth
Stimulated vaginal maturation

This study examined the potential of dehydroepiandrosterone (DHEA) as a physiological hormone replacement therapy at menopause.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms.

Author: LiuJames H

Improves Sexual Function
Preserves Bone Density
Treats Hot Flashes
Fluid Retention
Mastalgia
Vaginal Discharge
Weight Gain

Progestins, androgens, and tibolone were found to be effective in treating vasomotor symptoms in menopausal women.

Consensus Development Conference, NIHA conference organized by the NIH (National Institutes of Health) to develop consensus and recommendations on medical issues.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Efficacy and tolerability of compounded bioidentical hormone replacement therapy.

Author: VigesaaKristy A, DownhourNathan P, ChuiMichelle A, CappelliniLinda, MusilJohn D, McCallianDennis J

Menopause symptom relief
Bloating
Breast tenderness
Weight gain

Bioidentical hormone replacement therapy (BHRT) was well tolerated and relieved menopausal symptoms in 71.8% of the women surveyed. The most common side effects were weight gain (37.2%), breast tenderness (19.2%), and bloating (23.1%).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.